Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.52
-AU$0.02(-3.57%)
At close: 4:00 PM EDT
AU$0.52
-AU$0.02(-3.57%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$1.29
Previous CloseN/A
Volume5.87K
Average Volume (3M)80.85K
Market Cap
AU$46.52M
Enterprise ValueAU$51.92M
Total Cash (Recent Filing)AU$12.25M
Total Debt (Recent Filing)AU$7.80M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)-0.16
Shares Outstanding125,734,146
10 Day Avg. Volume166,983
30 Day Avg. Volume80,851
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)AU$36.60M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthContinued revenue growth indicates improving commercial traction and demand for Cyclopharm’s products. If sustained, expanding sales can support greater operating scale, broaden the customer base, and provide a foundation for eventual margin recovery as the business develops.
Recurring Consumables ModelRecurring consumables linked to an installed base can create repeat purchasing beyond initial generator sales. As more hospitals and imaging providers adopt Technegas, the installed base may support a more durable revenue stream and improve customer retention.
Meaningful Equity CushionA meaningful equity base gives Cyclopharm some capacity to absorb ongoing losses and continue operating while it works to improve performance. This cushion can provide greater flexibility than a business funded almost entirely by debt, although it does not remove financing pressure.
Bears Say
Severe Profitability DeteriorationNegative gross profit means the company is not currently covering direct costs through revenue, making losses more structurally serious than a temporary earnings shortfall. Unless pricing, product economics, or costs improve, revenue growth may not translate into stronger financial performance.
Persistent Cash BurnDeeply negative operating and free cash flow indicate that the business is consuming substantial cash to sustain operations. Continued burn increases dependence on external funding and could constrain investment, expansion, and the company’s ability to withstand further operating weakness.
Rising Leverage And Balance-sheet PressureHigher debt alongside declining equity increases financial risk and reduces balance-sheet flexibility. Rising leverage can amplify the effect of continued losses, increase funding needs, and leave fewer options for supporting growth without further borrowing or equity issuance.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.37 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$46.52M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Feb 24, 2027 which is in 124 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Aug 23, 2026. The company reported -AU$0.073 earnings per share for the quarter.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of 0.64%. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 125,734,146 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.073 in its last earnings report. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (92.31% Upside)
AU$1.00 (92.31% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 71%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.25%
12-Months-Change
Fundamentals
Return on Equity
-62.14%
Trailing 12-Months
Asset Growth
-11.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cyclopharm Limited
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(92.31% Upside)
Technical Analysis
Compumedics Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
OncoSil Medical Ltd
―
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―